NASDAQ: CBLLCeribell Inc Stock
$14.93+0.08 (+0.54%)
Updated Apr 21, 2025
CBLL Price
$14.93
Fair Value Price
N/A
Market Cap
$535.51M
52 Week Low
$10.01
52 Week High
$32.75
P/E
-4.4x
P/B
2.8x
P/S
4.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$65.44M
Earnings
-$40.46M
Gross Margin
86.7%
Operating Margin
-58.77%
Profit Margin
-61.8%
Debt to Equity
0.18
Operating Cash Flow
-$35M
Beta
1.53
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CBLL Overview
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CBLL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
B
CBLL
Ranked#68 of 103
Ranked#68 of 103
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.50 | A | |
| $22.62 | A | |
| $13.45 | A |
Be the first to know about important CBLL news, forecast changes, insider trades & much more!
CBLL News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CBLL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBLL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CBLL is good value based on its book value relative to its share price (2.8x), compared to the US Medical Devices industry average (3.74x)
P/B vs Industry Valuation
CBLL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CBLL due diligence checks available for Premium users.
Valuation
CBLL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.4x
Industry
40.34x
Market
27.14x
CBLL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.8x
Industry
3.74x
CBLL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CBLL's financial health
Profit margin
Revenue
$18.5M
Net Income
-$12.6M
Profit Margin
-67.9%
CBLL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CBLL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$225.4M
Liabilities
$34.2M
Debt to equity
0.18
CBLL's short-term assets ($217.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBLL's short-term assets ($217.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBLL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.0M
Investing
-$493.0k
Financing
$190.7M
CBLL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CBLL vs Medical Device Stocks
Ceribell Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.